Brigham and Women's Hospital in Boston is launching the first human clinical trial of a nasal vaccine that aims to prevent and slow the progression of Alzheimer's disease.
The hospital announced on Tuesday that the Phase I clinical trial will involve 16 participants between the ages of 60 and 85, who have early symptomatic Alzheimer's but otherwise are in general good health, CBS News reports. They will receive two doses of the vaccine, one week apart. The purpose of this Phase I trial is to determine if the vaccine is safe and what its dosage should be, and if successful, a larger trial will begin to test how effective it is.
A team at Brigham and Women's Ann Romney Center for Neurologic Diseases has spent the last 20 years researching the vaccine. It uses Protollin, a substance that is "designed to activate white blood cells found in the lymph nodes on the sides and back of the neck to migrate to the brain and trigger clearance of beta amyloid plaques — one of the hallmarks of [Alzheimer's disease]," the hospital said in a statement.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Dr. Howard L. Weiner is co-director of the Ann Romney Center for Neurologic Diseases, and led the vaccine research. He called the trial launch "a remarkable milestone" and "landmark," and said there is preclinical evidence suggesting the potential of the vaccine. Dr. Tanuja Chitnis, professor of neurology at Brigham and Women's and principal investigator of the trial, said research has "paved the way for us to pursue a whole new avenue for potentially treating not only [Alzheimer's disease], but also other neurodegenerative diseases."
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Measles cases surge to 33-year highSpeed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, changeSpeed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panelspeed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kidsSpeed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sickspeed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last yearspeed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive orderspeed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
